Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products in development include Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion; and NNZ-2591, a synthetic analogue of a naturally occurring neuropeptide that is in preclinical development for the treatment of various neurodegenerative disorders. The company has collaborative relationships with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.
neuren pharmaceuticals ltd
(NEU:Australian Stock Exchange Ltd)
697 Burke Road
Camberwell, VIC 3124
Phone: 61 3 9092 0480
|No competitor information is available for NEU.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact NEUREN PHARMACEUTICALS LTD, please visit www.neurenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.